Source: Υπουργείο Υγείας (CY) Revision Year: 2019 Publisher: Remedica Ltd, Aharnon Street, Limassol Industrial Estate, 3056 Limassol, Cyprus
Cinnaron 75 mg hard capsules.
| Pharmaceutical Form |
|---|
|
Hard capsules. Orange/yellow capsules. |
Each hard capsule containscinnarizine 75 mg.
Excipients with known effect:
Each hard capsule contains 48.7 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Cinnarizine |
Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction. |
| List of Excipients |
|---|
|
Capsule content: Sodium starch glycolate (Type A) Capsule body: Quinoline yellow (E104) Capsule cap: Quinoline yellow (E104) |
PVC/Aluminium blisters. Pack sizes of 20 and 1000 hard capsules.
PP containers with PE closures. Pack size of 1000 hard capsules.
Not all pack sizes may be marketed.
Remedica Ltd, Aharnon Street, Limassol Industrial Estate, 3056 Limassol, Cyprus
11726
Date of first authorization: 01 July 1988
Date of latest renewal: 20 November 2009
| Drug | Countries | |
|---|---|---|
| CINNARON | Cyprus, Estonia, Singapore |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
